Sulindac
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Sulindac: From NSAID Therapy to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Sulindac is a non-steroidal anti-inflammatory drug (NSAID); however, detailed original indication and mechanism-of-action data were not available in this Evidence Pack. The TxGNN model’s top-ranked prediction is Acromesomelic Dysplasia, Hunter-Thompson Type, a rare genetic skeletal dysplasia, but this prediction is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale text flags the mechanistic link as biologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — Sulindac is not currently marketed in the UK and no approved indication text was provided in the source data |
| Predicted New Indication | Acromesomelic Dysplasia, Hunter-Thompson Type |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available for Sulindac in this pack. Based on known pharmacology, Sulindac is a cyclooxygenase (COX)-inhibiting NSAID, traditionally used for pain and inflammation associated with musculoskeletal conditions such as osteoarthritis and rheumatoid arthritis.
The top-ranked predicted indication, Acromesomelic Dysplasia (Hunter-Thompson type), is a rare skeletal dysplasia caused by mutations in the GDF5/CDMP1 gene affecting the bone morphogenetic protein (BMP) pathway. There is no known interaction between COX inhibition and BMP signalling, and the pack’s own mechanistic-link narrative explicitly states this association is likely a statistical co-occurrence artefact of the knowledge-graph embedding, rather than a biologically grounded hypothesis. The same caveat applies to predictions ranked 2–8 (brachyolmia-related syndromes, myosclerosis, pseudoachondroplasia, brachydactyly-syndactyly syndrome, colobomatous microphthalmia-rhizomelic dysplasia syndrome, WHIM syndrome) — all are rare developmental or genetic disorders with no plausible link to NSAID pharmacology.
Two lower-ranked candidates merit note for context, though they were not the top-ranked prediction and are therefore not the primary focus of this report: rheumatoid vasculitis (rank 9, L4) has a plausible but weak indirect link via Sulindac’s anti-inflammatory use in rheumatoid arthritis, and hypermobility of coccyx (rank 10, L4, decision stage S1, “Research Question”) has the most coherent mechanistic rationale — NSAID-mediated prostaglandin suppression is a recognised approach to coccydynia pain management — though it still lacks any direct clinical or literature support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Sulindac currently holds no marketing authorisation in the United Kingdom. The Evidence Pack records a UK market status of “not marketed” with zero total licences on file as of the data cutoff (17 September 2026).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: UK-specific product warnings and contraindications for Sulindac could not be retrieved for this Evidence Pack and are flagged as a Blocking data gap (DG001), which prevents this candidate from progressing to an initial safety assessment (Stage S1) regardless of the strength of the efficacy prediction.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (Acromesomelic Dysplasia, Hunter-Thompson Type) has no supporting clinical trials or literature, and the mechanistic rationale itself acknowledges a lack of biological plausibility. Combined with a blocking data gap on UK product safety information, this candidate cannot proceed past the earliest screening stage.
To proceed, the following is needed:
- MHRA/SmPC-sourced warnings, contraindications, and drug interaction data for Sulindac (currently blocking)
- Confirmed mechanism-of-action documentation from DrugBank or an equivalent source
- If pursued further, re-evaluation should prioritise the lower-ranked but mechanistically more coherent candidates — hypermobility of coccyx (coccydynia) and rheumatoid vasculitis — over the top-ranked rare skeletal dysplasia prediction
- Should any candidate advance, dedicated searches for relevant clinical trials and literature, as none are currently on record
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.